University of California, Los Angeles (UCLA) Presents Data on MediciNova, Inc.'s MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence
6/19/2013 9:40:22 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, June 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the presentation of preliminary results from a Phase 1b study of MN-166 (ibudilast) in methamphetamine addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego on June 18, 2013. MN-166 was featured in both a poster session and a symposium at the meeting where leading researchers discussed the role of activated glia, and potential intervention with glial attenuators like MN-166, in drug abuse. Pre-clinical and early clinical results were summarized in the symposium session.
Help employers find you! Check out all the jobs and post your resume.
comments powered by